Adherence to HU and HRQOL in Patients With Sickle Cell Disease: An Intervention Study Using HU-Go App
Study Details
Study Description
Brief Summary
This project addresses three important research questions. First, adolescents and young adults (AYA) with sickle cell disease (SCD) and their parents/caregivers will be engaged to inform the (1) domains of health-related quality of life (HRQOL) most important to them, (2) frequency at which they are willing to complete them, and (3) other procedures related to the use, uptake and effect of the HU-Go app as a tool to improve hydroxyurea (HU) adherence. Second, this study seeks to utilize novel modern mobile technology using a multi-functional personalized platform to improve adherence to HU and measure HRQOL in youth with SCD, using NIH-endorsed PROMIS® measures, based on a conceptual model with predefined behavioral targets and mediators. Third, we plan to assess HRQOL changes and identify modifiable behavioral strategies that could serve as surrogates or predictors for HU adherence. This real-time feedback might empower self-directed changes in behavior that could improve adherence to HU.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Aim 1: Identify the needs, desires, concerns, and expectations of AYA patients with SCD and their parents/caregivers that will guide implementation of a mHealth tool, HU-Go, designed to improve adherence to HU. We will conduct semi-structured interviews with patients and their parents/caregivers. Transcripts will be independently coded and thematic analysis will be conducted.
Hypothesis 1: AYA patients with SCD and their parents/caregivers will identify specific features, content, and usability requirements of HU-Go.
Aim 2: Assess the longitudinal relationship of HU adherence to HRQoL domains, including fatigue and depression. HU adherence will be measured using electronic pill bottles, self-report measures, laboratory markers, and medication possession ratio (MPR). HRQOL will be assessed using PROMIS® measures.
Hypothesis 2: Low HU adherence is associated with impairment of HRQoL domains.
Aim 3: Conduct a single-arm, pilot study to determine the effect size associated with improvement in HU adherence after using HU-Go for 12 weeks. Adherence will be measured using self-report measures, laboratory markers and MPR.
Hypothesis 3: HU-Go will improve HU adherence by at least 20%.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Other: HU-Go app intervention arm Participants will use HU-Go app intervention arm for a total of 12 weeks. |
Other: HU-Go app
A novel multifunctional mobile app (HU-Go) to improve adherence to hydroxyurea in patients with sickle cell disease
|
Outcome Measures
Primary Outcome Measures
- Achieving feasibility based on the number of participants completed all study procedures within 6 months of study enrollment [3 months of study enrollment]
Feasibility is defined as having 80% or more of study participants complete the study within 6 months of enrollment
Secondary Outcome Measures
- Adherence to Hydroxyurea using Modified Morisky Adherence Scale 8-items [3 months of study enrollment]
Numerical value on a scale 0-8 (higher score indicating higher adherence to hydroxyurea)
- Adherence to Hydroxyurea using Visual Analogue Scale [3 months of study enrollment]
Numerical value on a scale 0-100% (higher score indicating higher adherence to hydroxyurea)
- Patient satisfaction with the smartphone app intervention (HU-Go) [3 months of study enrollment]
Customized patient satisfaction questionnaire, numerical value on a scale 0-10 (higher score indicating higher satisfaction with the app)
- HRQOL outcomes [3 months]
Patient reported outcomes measurement information system (PROMIS) measures, numerical value on a scale of 0-100 points, normal average for the general population is 50 with standard deviation of 10 points. Each HRQOL outcome domain score will be reported separately (higher T scores indicating worse pain, fatigue, depression and anxiety, and lower scores indicating worse physical functioning and peer relationships).
Eligibility Criteria
Criteria
Inclusion Criteria:
-
At least 12 years old at the time of study enrollment
-
Diagnosis of sickle cell disease (hemoglobin SS or SC or S/B 0 thalassemia) confirmed by hemoglobin electrophoresis
-
On hydroxyurea
-
Own or have access to a smartphone
-
Be able to speak and read English
Exclusion Criteria:
-
Chronic monthly transfusion support
-
Any hemoglobinopathy other than sickle cell disease
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Ann & Robert H Lurie Children's Hospital of Chicago | Chicago | Illinois | United States | 60611 |
Sponsors and Collaborators
- Ann & Robert H Lurie Children's Hospital of Chicago
Investigators
- Principal Investigator: Sherif M. Badawy, MD, MS, Ann & Robert H Lurie Children's Hospital of Chicago
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- IRB 2015-761